The OAK trial with the PD-L1 inhibitor atezolizumab is positive: This "me too" result may well change the advanced NSCLC landscape

In a post I wrote on the GRACE website, I describe how the press release of the positive results from the phase III OAK trial of atezolizumab (Tecentriq) vs. docetaxel in unselected patients with previously treated advanced NSCLC is a completely unsurprising result.  It will likely lead to the approval of this agent as the third entrant into an already over-crowded market, with nivolumab and pembrolizumab already approved for what will likely be a very similar indication. Nevertheless, I think the approval may provide an option that is just different enough to make this agent a leader in the second line space.

I hope you'll be interested in reviewing that post and would welcome your comments, questions, and objections.